ENTX Receives FDA Feedback
ENTX - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.